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nal blood flow autoregulation was investigated in anesthetized
C57Bl6 mice using time- and frequency-domain analyses. Autoregu-
lation was reestablished by 15 s in two stages after a 25-mmHg step
increase in renal perfusion pressure (RPP). The renal vascular resis-
tance (RVR) response did not include a contribution from the macula
densa tubuloglomerular feedback mechanism. Inhibition of nitric
oxide (NO) synthase [NG-nitro-L-arginine methyl ester (L-NAME)]
reduced the time for complete autoregulation to 2 s and induced
0.25-Hz oscillations in RVR. Quenching of superoxide (SOD mimetic
tempol) during L-NAME normalized the speed and strength of stage
1 of the RVR increase and abolished oscillations. The slope of stage
2 was unaffected by L-NAME or tempol. These effects of L-NAME
and tempol were evaluated in the frequency domain during random
fluctuations in RPP. NO synthase inhibition amplified the resonance
peak in admittance gain at 0.25 Hz and markedly increased the gain
slope at the upper myogenic frequency range (0.06–0.25 Hz, identi-
fied as stage 1), with reversal by tempol. The slope of admittance gain
in the lower half of the myogenic frequency range (equated with stage
2) was not affected by L-NAME or tempol. Our data show that the
myogenic mechanism alone can achieve complete renal blood flow
autoregulation in the mouse kidney following a step increase in RPP.
They suggest also that the principal inhibitory action of NO is
quenching of superoxide, which otherwise potentiates dynamic com-
ponents of the myogenic constriction in vivo. This primarily involves
the first stage of a two-stage myogenic response.
renal circulation; perfusion pressure; renal vascular resistance; admit-
tance gain; afferent arteriole
MOST VASCULAR BEDS REGULATE blood flow according to meta-
bolic conditions to provide adequate nutrient delivery and
effective waste removal. Control of renal blood flow (RBF) is
unique among peripheral vascular beds, as the principal goal is
not to satisfy metabolic demands, but rather to stabilize glo-
merular capillary pressure at a level that provides an adequate
glomerular filtration rate. This is achieved by an efficient
autoregulatory mechanism(s) that adjusts glomerular afferent
arteriolar diameter in response to fluctuations in renal perfusion
pressure (RPP). Of equal importance, this process protects
glomerular capillaries from excessive pressures that can cause
barotrauma, glomerular injury, and renal failure. Several in-
trinsic mechanisms regulate renal vascular resistance (RVR) in
response to changes in RPP (3, 13). In common with most
organs, changes in RPP invoke an intrinsic myogenic mecha-
nism in the vascular smooth muscle cells (VSMC) of renal
resistance vessels, which stabilizes downstream capillary pres-
sures. The unusually high efficiency of blood flow autoregu-
lation in the kidney may be due to an exceptionally strong
myogenic mechanism and perhaps the unique contribution of
additional mechanisms involving tubuloglomerular feedback
(TGF), such as distal tubular macula densa (MD) cell signaling
to the afferent arteriole, termed MD-TGF (3, 13).
Classically, autoregulation has been assessed by determining
RBF responses to progressive increases or decreases in RPP
with pressure steps lasting 1–2 min to define steady-state
autoregulation (13, 15, 33). This produces a static, integrated
autoregulatory response that provides an index of overall
efficiency, but it does not differentiate between the relative
contributions of individual mechanisms. Alternative ap-
proaches have analyzed dynamic components of the RPP/RBF
relationship in either the time or the frequency domain to
isolate the contributions of multiple mechanisms operating in
the kidney. The results of these dynamic analyses have re-
vealed distinct components adjusting RVR or vascular admit-
tance based on different time constants of the more rapid
myogenic mechanism and the slower MD-TGF mechanism. In
the time domain, the increases in RVR to an abrupt step
increase in RPP reveals distinct phases or stages in the rate of
the response that have been attributed to the sequential oper-
ation of the myogenic mechanism followed by input from
MD-TGF. In the frequency domain, spectral analysis of rela-
tive changes in RBF vs. RPP (admittance gain) distinguish
between the operation of the myogenic mechanism at the upper
end of the autoregulatory frequency range (0.08–0.25 Hz) and
the MD-TGF mechanism at the lower end of the frequency
range (0.01–0.02 Hz) (13, 15, 18, 33). In addition, both
approaches have advanced evidence suggesting the operation
of a third and perhaps even a fourth mechanism (13, 34, 36).
The relative contributions of the myogenic and MD-TGF
mechanisms to RBF autoregulation and their interactivity are
important questions that remain somewhat controversial. In
general, most transfer function studies identify one frequency
range for the myogenic response and one for MD-TGF, oper-
ating at roughly one cycle every 5 and 30 s, respectively.
However, there are examples of RBF autoregulation when two
stages are observed in the frequency band encompassing the
myogenic response (0.08–0.2 Hz) (41, 89, 91). A third com-
ponent has been identified in the frequency domain operating at
0.01 Hz (81). In the time domain, the RVR adjustments to a
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rapid step increase in RPP generally reveal three stages, with
transition points at 5 and 20 s, with achievement of complete
RBF autoregulation between 20 and 90 s, suggesting the
participation of two or three components (13, 24, 25, 33, 34).
The most rapid increase in RVR to a step increase in RPP
occurs within the initial 4–5 s and is commonly accepted to
represent the myogenic response. A second stage is noted
between 5 and 20 s and may represent the myogenic mecha-
nism in the absence of MD-TGF (25) or MD-TGF (19, 20,
34–37). In some studies, RBF is completely autoregulated by
15–25 s with a two-stage increase in RVR (24, 25, 95, 96). In
others, a slower third stage is observed between 25 and 60 s
(19, 20, 27, 34–37). The mechanism mediating the third
component, if evident, is not known. It usually reaches com-
pletion by 60 s and may represent MD-TGF, as it can be
abolished by inhibition of MD-TGF with a loop diuretic
(34–36).
Nitric oxide (NO) appears to exert a pronounced blunting
effect on the strength and possibly the rate of the myogenic
response. In the time domain, NO synthase (NOS) inhibition
by NG-nitro-L-arginine methyl ester (L-NAME) increases the
speed and magnitude of the myogenic response such that
complete RBF autoregulation is attained within 10 s (19, 20,
33, 35, 37, 95). In the frequency domain, the myogenic re-
sponse between 0.08 and 0.25 Hz becomes stronger as indi-
cated by a greater and more rapid decrease in admittance gain
in that frequency range (79, 80, 88). In contrast to NO,
increased superoxide anion (O2) is a positive modulator of
myogenic tone in isolated afferent arterioles (49, 50, 76) and
arteriolar constriction stimulated by MD-TGF (54, 75, 93, 94),
at least under steady-state conditions. Increased RPP increases
O2 production by arteries and arterioles (44, 84), including the
renal afferent arteriole (50). However, the influence of O2 on
the dynamic characteristics of RBF autoregulatory mechanisms
is not known, in either the presence or absence of NO.
In the present studies, we have integrated time and fre-
quency domain-based approaches to provide a more compre-
hensive and definitive picture of the autoregulatory response to
RPP changes in the mouse kidney. An important feature of our
in vivo investigation is the development of functional corre-
lates between the time and frequency domains to assess the
roles of NO and O2 in paracrine modulation of renal autoreg-
ulatory mechanisms by inhibiting NO synthesis with L-NAME
and O2 dismutation with tempol. We have identified two
stages in the myogenic response, independent of MD-TGF, and
provide new information about the differential actions of NOS
inhibition with L-NAME and O2 dismutation with tempol on
the initial, most rapid myogenic component. The data suggest
that NO attenuates the myogenic response largely by interfer-
ing with the vasoconstrictor action of O2 and supports a
previously unrecognized direct role for O2 in regulating the
dynamic characteristics of the myogenic autoregulatory re-
sponse.
METHODS
Male C57Bl6 mice bred in our facility consumed an irradiated
commercial rodent diet containing 0.1% NaCl (Teklad 2920X) and
drank tap water ad libitum. All experimental protocols and procedures
were approved by the institutional animal use and care committee at
the University of North Carolina at Chapel Hill and conformed to
National Institutes of Health Guidelines for the Care and Use of
Laboratory Animals.
Preparation of animals. Animals were anesthetized with an intra-
peritoneal injection of pentobarbital sodium (60 mg/kg body wt) and
placed on a heated operating table with servo-control to maintain body
temperature at 37°C. The trachea was intubated with a PE-90 cannula
to facilitate spontaneous breathing. A jugular vein was cannulated
with three PE-10 catheters for infusion of maintenance solutions, test
agents, and supplemental doses of anesthetic. Isotonic saline was
infused continuously intravenously at 7 l/min, and 2% BSA in saline
at 3 l/min (Fraction V, Sigma). RPP was equated with arterial
pressure (AP) monitored from a femoral artery with a pressure
transducer (Statham p23dB) connected to a Hewlett Packard carrier
amplifier (model 8805B). Urine was drained through a PE-90 cannula
secured in the bladder at the dome. The right kidney was exposed
through a retroperitoneal incision, and the renal artery mobilized free
of connective tissue to allow installation of an ultrasonic transit time
flow probe (0.5PSB transducer connected to a TS420 flow monitor;
Transonic). Renal nerves were removed during this procedure to
eliminate reflex sympathetic input to the kidney that could influence
RBF during alterations in RPP.
RPP and RBF were digitized at 120 Hz with a sample-and-hold
A/D converter (Data Translation, DT9816 A/D board) and displayed
on a PC monitor using a data acquisition program based on the DtEZ
program suite (Data Translation). At noncritical times, data were
averaged in 1-s bins. During data collection periods for analysis of
autoregulatory responses, the incoming RPP and RBF data streams
were smoothed with a low-pass Butterworth fifth-order digital filter
with the frequency cutoff set to 2 Hz and then down-sampled to 10 Hz
for storage on disk. Data were collected for 3- or 35-min periods
during time-domain and frequency-domain analyses, respectively.
Regulation of RPP by aortic snare. RPP was regulated by adjusting
the tension applied to a snare of 8-0 silk suture (0.025 mm diameter)
threaded around the abdominal aorta rostral to the right renal artery.
After placement around the aorta, the two ends of the snare were tied
together, attached to 6-0 suture thread, and drawn through an 18-
gauge trocar bent into a rounded 70° angle. A short length of PE-160
tubing was used as an interface between the tip of the trocar and the
aorta. The hub of the trocar was clamped to a micromanipulator, and
the suture emerging from the hub was attached to a second microma-
nipulator positioned in line with the trocar. The PE-160 tubing at the
trocar tip was positioned adjacent to the aorta so that aortic diameter
could be regulated by applying tension to the snare with the second
micromanipulator without causing physical disturbance to the sur-
rounding tissue. The 8-0 suture generated minimal friction within the
trocar and allowed rapid, unimpeded dilatation of the aorta upon
abrupt release of tension. In this way, RPP measured at the femoral
artery could be reduced precisely and released rapidly by adjusting the
tension on the snare.
Assessment of autoregulation dynamics in the time domain. Dy-
namic renal autoregulatory efficiency was assessed from the RVR
response to an abrupt 20- to 25-mmHg step increase in RPP, as
described previously (34–37). Briefly, RPP was reduced from the
basal level by tightening the aortic snare until a 20- to 25-mmHg
reduction was achieved. RPP was maintained at this level for 1 min
before the snare was quickly released to cause RPP to rebound rapidly
back to the basal level. The reduced RPP was always maintained
within the autoregulatory range (80 mmHg); a trial was discontin-
ued if RBF showed a sustained decrease below control levels during
the RPP reduction period. Autoregulatory progress was assessed at
0.1-s intervals after the RPP step by calculating the extent to which
complete autoregulation was achieved at that time expressed as a
percentage of perfect autoregulation. The RVR necessary for perfect
autoregulation was obtained by dividing average RPP in the second
minute after release by the average RBF before release. In this
approach, a perfect autoregulatory response to the RPP step would
require no change in RBF and produce 100% autoregulatory effi-
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ciency at every time point in the measurement period. Conversely, if
RBF increased in direct proportion with the RPP step, there would be
no autoregulation, and autoregulatory efficiency would remain at 0%
for all measurement times. In the mice studied here, autoregulation
reached 100% efficiency within 15 s after the RPP step during control
conditions.
Assessment of autoregulation dynamics in the frequency domain.
After installation of the aortic snare, the thread passing between the
two micromanipulators was linked to the plunger of a 0.25-ml glass
tuberculin syringe positioned vertically directly below the snare
thread. A length of PE-320 tubing linked the syringe to a water-filled
chamber pressurized by a rubber diaphragm connected to a Ling
Shaker motor (Ling Dynamic Systems, model 203). Random pressure
fluctuations in the syringe were produced by driving the Ling motor
with a white noise signal after conditioning with a 2-Hz low-pass
filter. The resulting motion of the syringe plunger was delivered to the
aorta via tension on the snare to produce random changes in RPP.
Digitized and filtered RPP and RBF signals were collected for 35 min
and stored on disk for offline analysis.
The RPP and RBF time series data were processed by fast Fourier
transformation using repetitive 4,096 sample segments that were
normalized to zero mean and detrended. According to Welch’s
method (92), data segments were overlapped by 50% to reduce noise
and variance. Segments were tapered at each end using a Kaiser
window with a shape factor set to approximate a normal Gaussian
curve. Eight fast Fourier transformations of RBF and RPP data were
obtained during each experimental period. The transforms were sub-
jected to cross-spectral analysis to provide measurements of admit-
tance gain, phase relationships, and coherence values for RBF and
RPP. An admittance gain of 1.0 is equivalent to 0 dB and corresponds
to equivalent power in RBF and RPP oscillations. Gain values below
unity signify attenuated power in RBF oscillations relative to RPP,
which is indicative of active RBF autoregulation at a given frequency
band. Admittance gain values above unity indicate augmented RBF
oscillations relative to RPP, perhaps caused by a decrease in RVR due
to passive vascular dilation during the pressure wave. The phase
relationship between RPP and RBF routinely generated positive phase
angles, since RBF oscillations always preceded the corresponding
change in RPP. This has been reported in previous studies on the renal
and cerebral vasculature (18) and is consistent with the vasculature
operating as a high-pass filter with respect to blood flow oscillations
(22). Coherence between RBF and RPP spectra represents the fraction
of the variance of the RBF signal at a given frequency that can be
accounted for on the basis of a linear operation on the RPP signal at
that frequency. Coherence would be unity, if there were no variables
other than RPP affecting RBF, assuming no measurement error.
Experimental protocols. Experiments were divided into three pe-
riods. Control data were obtained in the first period, followed by
administration of the NOS inhibitor L-NAME (25 mg/kg iv) in the
second period. In the third period, the cell-permeable SOD mimetic
tempol was infused (4 mg·kg1·min1 iv) to produce suppression of
superoxide activity during NOS inhibition. A 20-min stabilization
period was allowed after L-NAME administration and the start of
tempol infusion. In time-domain studies, four RPP steps were per-
formed in each period. Results were averaged in each period to
provide three averaged responses for each animal. The same basic
protocol was followed in frequency-domain experiments. Data were
collected at 10 Hz for 35 min in the control, L-NAME, and combined
L-NAME  tempol periods. Derived data from transfer function
analyses for each animal were averaged from the eight data segments
extracted from each collection period.
Our interpretation of results obtained during L-NAME is based on
its inhibitory action on NOS and consequent reduction in NO produc-
tion and local concentration of NO. L-Arginine analogs, such as
L-NAME or NG-nitro-L-arginine, are known to act as specific inhibi-
tors of NOS isoforms and NO production in health (46, 73). Arginine
analogs are commonly used to test the effect of reduced NO on
steady-state (8, 29, 58) and dynamic characteristics (32, 35, 91) of
RBF autoregulation in healthy kidneys. Renal NOS enzymes are
tonically active under basal conditions, and NOS inhibition is asso-
ciated with reductions in renal tissue NO concentration and urinary
excretion of the NO metabolites nitrate/nitrite (43, 57, 59–61). Acute
suppression of NO production leads to increased AP, renal vasocon-
striction, decreased RBF, and reduced sodium excretion (46, 48, 63,
73, 77). These effects can be reversed by excess L-arginine or a NO
donor, such as sodium nitroprusside or cell-permeable 8-bromo-
cGMP (42, 48, 59, 62, 74). NOS inhibition also attenuates acetylcho-
line-induced urinary excretion of cGMP, an index of renal NOS
activity, and the concomitant renal vasodilation (8, 82). These effects
are independent of the constrictor actions of angiotensin II (ANG II)
or the sympathetic nervous system, at lease in conscious, unstressed
animals (7, 46, 73).
The contribution of MD-TGF to the autoregulatory response was
tested in other mice by blocking MD-TGF with ureteral obstruction
(UO) during an osmotic diuresis. To induce the diuresis, a 10% wt/vol
solution of mannitol in 0.45% saline was infused intravenously at a
rate of 20 l/min. When urine flow had increased from the basal level
of 1–2 to 20–30 l/min, the right ureter was tied off at the renal
pelvis. After 10 min for equilibration, experiments proceeded with
step increases or random fluctuations in RPP.
In a separate series of experiments, the RPP step protocol was
performed before and during intravenous infusion of arginine vaso-
pressin (AVP) titered to produce an increase in RPP equal to that
caused by L-NAME treatment (300 ng/min at 30 l/min). These data
controlled for effects of increased RPP caused by L-NAME that were
unrelated to NO inhibition. A second series tested the direct effect of
the hypotensive action of tempol on the autoregulatory response after
treatment with L-NAME in the frequency domain. In these mice,
tempol was omitted from the third period, and instead the aortic snare
was tightened to reduce mean RPP to the control level. Random
fluctuations were induced at this mean pressure in the manner de-
scribed.
Data analysis: time domain. The increase in RVR following a RPP
step was expressed as the percent return to 100% autoregulation based
on the RBF and RPP values before the RPP step. The resulting RVR
response curves were analyzed up to 60 s following the RPP step. An
initial rapid decrease and increase in RVR over the first 0.7 s were
excluded from the analysis, as this has been identified as a passive
response to the initial surge in pressure within the vasculature (34,
96). Many studies on rodents have shown that the restoration of RBF
following the RPP step occurs in discrete stages that can be attributed
to the operation of individual components in the autoregulatory
response (27, 34, 96). Two distinct stages were evident in the RVR
responses in our animals, with 100% efficiency generally occurring
during the second stage 15 s after the RPP increase. The slopes for
each stage and transition points were analyzed by multiple-regression
analysis to produce best fit data using commercial software (Prism
6.5, Graphpad software). To provide unambiguous identification of
slopes and time points, the transition point between stages 1 and 2 was
constrained to occur no sooner than 1 s after the RPP step. A second
transition point was set to occur no earlier than 15 s, which provided
a value corresponding to the end of stage 2. Slopes and transition
points in each period were compared by two-way ANOVA or by t-test
where appropriate. The overall autoregulatory efficiency was assessed
by comparisons of mean RBF during 60 s of reduced RPP immedi-
ately before the RPP step and mean RBF between 90 and 120 s after
the RPP step. The efficiency of steady-state RBF autoregulation was
equated with the efficiency recorded between 50 and 60 s.
Data analysis: frequency domain. The imposed fluctuations in RPP
required persistent tension on the aortic snare. Thus mean RPP in
these experiments was 10 mmHg lower than the basal or spontane-
ous RPP in the absence of aortic occlusion.
Transfer function analyses of RPP and RBF were performed on
data derived from the real and imaginary components of their cross
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spectrum, which constitute the cospectrum and quadrature spectrum,
respectively. Phase angle was calculated from the arctangent of the
cospectrum and quadrature spectrum at each frequency step and
expressed in degrees. Admittance gain was calculated as the square
root of summed squares of the cospectrum and quadrature spectrum
and adjusted to correct for the large difference between raw RPP and
RBF values. The correction factor was calculated as the ratio of
average fluctuation amplitudes in untransformed RPP and RBF traces.
Coherence was calculated as the squared cross-spectral density fac-
tored by the product of RPP and RBF autospectral densities at each
frequency step and expressed on a ratio scale between 0 and 1.
Comparisons of the slopes of admittance gain in the 0.06- to 0.2-Hz
frequency range associated with the myogenic mechanism were made
using a linear frequency scale. This provided more resolution and the
opportunity to perform multiple regression analyses of the slope
values using the same procedure as described for the RPP step
response. The minimum value for the transition point between two
stages was set to occur at no less than 0.155 Hz.
Chemicals used. Pentobarbital, L-NAME, tempol, and AVP were
obtained from Sigma Chemical.
RESULTS
Average body weight of all animals in the study was 28.2 
0.5 g, with a right kidney weight of 0.216  0.005 g (n  40).
During control conditions, mean AP was 105  2 mmHg, and
RBF averaged 8.58  1.51 ml·min1·g kidney wt1.
The mean autoregulatory efficiency curve of RVR following
a 25-mmHg step increase in RPP during the control state is
shown in Fig. 1A. The trace shows the time course for rees-
tablishment of autoregulation over the first 60 s after the RPP
step from 80 to 105 mmHg. The RVR response curve had
several distinct phases, beginning with an immediate decline
for 0.3 s, followed by a sharp rebound between 0.3 and 0.7
s (Fig. 1A, inset). These initial RVR changes have been
attributed to passive distension and subsequent elastic recoil
of the vasculature caused by the immediate impact of the
RPP increase (96). The passive nature of this immediate
response is confirmed by its persistence after elimination of
the active autoregulatory response by calcium channel
blockers (34). The active autoregulatory RVR response was
composed of two distinct stages with a transition at 5 s
(Fig. 1). Each stage contributed 50% of the RVR response,
leading to perfect autoregulation that was attained by 13 s.
The second stage continued beyond 100% and ended at 19
s after the RPP step, with a total efficiency of 115%. Mean
slope values for the two stages, transition points, and com-
pletion times for the second stage are given in Table 1. The
prestep RPP and RBF values were mean values over 60 s
immediately before the RPP step. The poststep RPP and
RBF values were recorded between 90 and 120 s after the
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Fig. 1. Changes in renal vascular resistance (RVR) in the time domain in response to a step increase in renal perfusion pressure (RPP) before (A) and during
inhibition of macula densa-tubuloglomerular feedback (MD-TGF) with mannitol  ureteral obstruction (UO; B) (n  7 mice). Insets magnify changes in the
first 10 s after the RPP increase showing RVR (solid lines) and BP (dashed lines). Changes are shown in admittance gain (C) and phase (D) in the frequency
domain during random oscillations in RPP before (solid line) and during inhibition of MD-TGF with mannitol  UO (dashed line) (8 mice). Values are
means  SE (dotted lines).
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RPP step. It is clear that that RBF was efficiently autoregu-
lated over this time frame. The fact that RBF ended up
slightly lower than the prestep starting level suggests an
element of super-autoregulation.
To determine the contribution of MD-TGF to the RVR
response in the time domain, similar experiments were per-
formed after inhibition of MD-TGF by means of a 10%
mannitol diuresis, combined with complete ureteral occlusion
(mannitol/UO) (18). As is shown in Fig. 1B, inhibition of
MD-TGF did not change the general shape of the RVR re-
sponse, which achieved 100% efficiency by 13–14 s. Thus the
initial two stages of the autoregulatory adjustments in RVR
persisted after suppression of MD-TGF and are most likely
exclusively due to a myogenic mechanism(s). In the absence of
MD-TGF, each stage still accounted for 50% of perfect
autoregulation. Nevertheless, it is noteworthy that there was a
28% increase in the slope of stage 1 (P  0.001), whereas the
slope of stage 2 decreased insignificantly (Table 1). Unlike the
control state, during mannitol/UO the final autoregulatory
RVR response did not exceed 100% of perfect autoregulation
(Fig. 1B). These findings suggest that MD-TGF exerted a small
inhibitory effect on the initial myogenic response, probably
due to a dilatory action of MD-TGF during the reduced RPP
that tended to offset the initial RVR increase when RPP was
abruptly increased. Also, the MD-TGF mechanism appeared to
be implicated in an RVR overshoot beyond 100% efficiency
that was commonly observed between 15 and 60 s in trials
when MD-TGF was active, contributing to a small increase in
RVR after completion of the myogenic response.
Our interpretation of the myogenic mechanism(s) being the
major, if not exclusive, contributor to RBF autoregulation
under the described experimental conditions depends on the
effectiveness of mannitol/UO in inhibiting MD-TGF. This was
tested by transfer function analysis of renal vascular admit-
tance. Admittance gain derived from the transfer function
during control conditions and mannitol/UO is shown in Fig.
1C. Reading the traces from right to left, control admittance
gain showed a steep decline beginning at 0.2 Hz, the corner
frequency for onset of the renal myogenic autoregulatory
response (15, 18, 33). Admittance gain then plateaued at 0.06
Hz, with a second decline beginning at 0.025 Hz. The latter is
commonly identified as the onset of the MD-TGF mechanism
(2, 18, 30, 52). A third gain reduction occurred at very low
frequencies (0.005 Hz), but the coherence between the RBF
and RPP signals in this range was too low to permit confident
interpretation.
We observed that mannitol/UO did not affect the slope of the
myogenic response between 0.2 and 0.06 Hz, whereas the
change in admittance gain associated with MD-TGF activity at
lower frequencies was virtually eliminated (Fig. 1C). Effective
abrogation of MD-TGF by mannitol/UO was also evident in
the elimination of a pronounced increase in phase angle present
in the control state at frequencies associated with MG-TGF
activity (Fig. 1D). An increasing phase angle in this frequency
range indicates an increasing independence of RBF from the
passive effects of RPP fluctuations, consistent with strong
MD-TGF activity. These findings extend previous studies
showing that full autoregulatory efficiency can be achieved by
myogenic mechanisms without the involvement of MD-TGF
(18, 30).
To assess the role of NOS inhibition on the dynamic char-
acteristics of the renal myogenic mechanism(s), the RPP step
protocol was repeated after L-NAME inhibition of NOS activ-
ity and NO production. Dramatic effects were observed in both
the time- and frequency-domain experiments. Renal autoregu-
latory efficiency in the time domain increased to 170% within
2 s after the RPP step (Fig. 2). This rapid increase in RVR
constituted the first upswing of a pronounced oscillatory re-
Table 1. Renal vascular resistance response to a RPP step increase before and during inhibition of macula densa-
tubuloglomerular feedback inhibition with mannitol and complete unilateral ureteral obstruction
RPP, mmHg RBF, ml·min1·g KW1 Slope, %/s Termination Point, s
Prestep Poststep Prestep Poststep Stage 1 Stage 2 Stage 1 Stage 2
Control 80  1 105  2 7.3  0.6 7.2  0.6 15.3  0.9 4.7 0.2 4.7 0.3 18.1 0.3
Mannitol/UO 81  1 105  2 5.8  0.5 6.0  0.5 19.6  1.2* 3.7 0.2 3.5 0.1 18.4 0.4
Values are means  SE; n  7 mice. RPP, renal perfusion pressure; RBF, renal blood flow; KW, kidney weight; UO, ureteral obstruction. *P  0.001 vs.
control.
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Fig. 2. Changes in RVR in the time domain in response to a step increase in RPP before (left) and during the inhibition of nitric oxide synthase (NOS) activity
by NG-nitro-L-arginine methyl ester (L-NAME; middle) and during NOS inhibition plus quenching of superoxide anion (O2) by tempol (right). Insets show the
first 10 s of the RVR response, including the initial passive stages and the onset of the active myogenic response (solid lines, left axes) and RPP (dashed lines,
right axes). Values are means  SE (dotted lines; n  9 mice).
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sponse at a frequency of 0.25 Hz, which persisted for 1–2 min
with progressively diminishing amplitude. Following the initial
stage 1 rise in RVR during L-NAME, the mean slope during
oscillations was not different from the slope of stage 2 in the
control response and terminated at the same point after the RPP
step. This indicates that the oscillatory response originated in
stage 1 and persisted throughout stage 2 as a modulating effect
on the slope of the underlying response.
Additional experiments tested the notion that the effects of
NOS inhibition were due, at least in part, to the enhanced
vasomotor activity of O2. To this end, we infused the cell-
permeable SOD mimetic tempol during L-NAME inhibition of
NOS. Slopes and transition points of the RVR responses to the
step change in RPP during control, L-NAME, and L-NAME 
tempol periods are shown in Fig. 2 and are summarized in
Table 2. In essence, superoxide inhibition with tempol reversed
the stimulatory action noted during NOS inhibition on the
initial rate of the myogenic autoregulatory response (stage 1)
and virtually eliminated the oscillations in RVR following the
RPP step, consistent with a major potentiating action of O2 on
stage 1 of myogenic vasoconstriction in the absence of NO.
Stage 2 of the myogenic response was similar to that observed
during control conditions. The data indicate that that NO
synthesis inhibition leads to an exaggerated myogenic re-
sponse. The exaggerated myogenic response was normalized
by tempol, an effect suggesting an exaggerated vasoconstrictor
action of O2 during NOS inhibition.
The increase in basal AP from 105 to 128 mmHg after
L-NAME is a consideration, as this alone might influence the
rate of the autoregulatory response (90). This was tested by
repeating the RPP step in a separate group of mice before and
during intravenous infusion of AVP at a rate that produced a
stable increase in AP similar to that produced by L-NAME. The
general pattern of the autoregulatory response in these AVP-
infused mice at 126 mmHg was not different from the control
response seen at the basal pressure of 100 mmHg, and no
oscillations in RVR occurred following the RPP step. These
results are presented in Fig. 3 and Table 3. There was an
increase in the slope of stage 1 from 17.7 to 28.6%/s (P 
0.001). This may reflect a relatively small enhancement of the
myogenic response due to the increased RPP compared with
the effects of NOS inhibition with L-NAME on the stage 1
slope (increase from 15.5 to 188.3%/s) when RPP increased to
a similar extent. The duration of stage 1 was reduced after
AVP, leading to a transition to stage 2 at 2.8 s vs. 4.2 s during
control conditions. This also might reflect a response to the
higher basal RPP. It is notable that there were reciprocal
percent changes in the slope and end point of stage 1 after
AVP, suggesting that a similar degree of vasoconstriction was
achieved over a shorter time period, which accounted for
60% of full autoregulatory efficiency. The slope of stage 2
was not altered during AVP-induced hypertension. These data
extend previous results, showing that the dynamics of RBF
autoregulation are largely unaffected by hypertension produced
by ANG II or phenylephrine (20, 35, 71, 80).
The effects of NOS inhibition followed by superoxide dis-
mutation on the autoregulatory response were investigated
further by performing transfer function analyses of RPP/RBF
relations. The black trace in Fig. 4A shows the complete
admittance gain relationship between 0.001 and 1 Hz in the
control state. The presence of a myogenic component between
0.2 and 0.06 Hz and MD-TGF between 0.02 and 0.009 Hz was
clearly evident. After L-NAME (red trace), a prominent reso-
nance peak appeared in the admittance gain between 0.3 and
0.2 Hz, with a peak 200% above unity at 0.25 Hz. This
frequency corresponds to the 0.25-Hz oscillations in RVR
caused by NOS inhibition in the time domain. The slope of
admittance gain in the myogenic region was clearly increased
by L-NAME and resulted in a reduction in relative gain from
2.0 at 0.2 Hz to 0.4 at 0.06 Hz, a gain value that in the control
state required the combined operation of MD-TGF and myo-
genic mechanisms. As in the time domain, the increased
magnitude of the myogenic response was largely reversed by
tempol (blue trace), which also reduced the amplitude of the
resonance peak at 0.25 Hz close to control levels. Inspection of
the admittance gain trace between 0.02 and 0.001 Hz after
tempol reveals the reappearance of a characteristic MD-TGF
signature that was suppressed during L-NAME alone. This
suggests that the absence of MD-TGF activity following L-
NAME treatment was likely due to enhanced myogenic con-
tractility rather than inhibition of the MD-TGF signaling mech-
Table 2. Effects of L-NAME and tempol on the autoregulatory responses of renal vascular resistance to a RPP step
RPP, mmHg RBF, ml·min1·g KW1 Slope, %/s Termination Point, s
Prestep Poststep Prestep Poststep Stage 1 Stage 2 Stage 1 Stage 2
Control 82  1 106  1 9.4  0.6 9.0 0.6 15.5 0.8 3.4  0.1 4.12  0.16 19.0  0.3
L-NAME 103 1 129  1 2.8  0.4 2.6 0.4 188.3 21.3† 1.4  0.2 1.23  0.06 0.8  1.7
L-NAME  tempol 74  1 97  1 2.2  0.4 2.0 0.4 52.6 6.7† 3.6  0.2 2.20  0.03 3.5  1.1*
Values are means  SE; n  9 mice. L-NAME, NG-nitro-L-arginine methyl ester. *P  0.01 and †P  0.001 vs. control.
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Fig. 3. Changes in RVR in the time domain in response to a step increase in
RPP before (control; black) and during acute arginine vasopressin (AVP)-
induced vasoconstriction and hypertension (red). Insets show the initial 10 s of
the RVR response (left axes) and RPP (right axes). Values are means  SE
(dotted lines; n  6 mice).
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anism per se. The mean RPP and RBF values for these
experiments are presented in Table 4.
Phase and coherence relationships between RPP and RBF
are shown in Fig. 4, C and D. The phase transition between
0.2 and 0.06 Hz during control conditions was strongly
accentuated after NOS inhibition, indicating the increased
strength of the myogenic mechanism in this frequency
range. This was also the case in the MD-TGF range (0.025
Hz) after L-NAME, albeit less pronounced, which is consis-
tent with the loss of the MD-TGF signature in admittance
gain after L-NAME. Interestingly, the phase relationship
between RPP and RBF after tempol was restored to the
control level, an observation consistent with the apparent
restoration of MD-TGF seen in the admittance gain traces.
In the control and L-NAME  tempol periods, coherence
was greater or equal to 0.5 for frequencies 	0.009 Hz, thus
providing strong confidence for the derived parameters at this
frequency and above. Coherence was less well sustained at low
frequencies during L-NAME alone, coincident with the low ad-
mittance gain. This indicates a more complex, nonlinear relation-
ship between RPP and RBF, perhaps fueled by the enhanced
action of superoxide on the vascular contractile response.
It is reasonable to expect that the distinct stages apparent
in the myogenic response during control, L-NAME, and
L-NAME  tempol periods in the time domain are also
evident in the frequency domain. To assess this prediction,
the section of admittance gain associated with the myogenic
response in the frequency domain (0.06 – 0.25 Hz) was
Table 3. Effect of AVP-induced hypertension on the autoregulatory response of renal vascular resistance to a RPP step
RPP, mmHg RBF, ml·min1·g KW1 Slope, %/s Termination Point, s
Prestep Poststep Prestep Poststep Stage 1 Stage 2 Stage 1 Stage 2
Control 77 3 101 4 6.1  0.3 5.9  0.3 17.7 0.8 4.6  0.1 4.2  0.2 17.0  0.2
AVP 98 2 127 3 7.1  1.3 7.3  1.3 28.6 1.6† 4.9  0.1 2.8  0.1* 15.7  0.2
Values are means  SE; n  6 mice. AVP, arginine vasopressin. *P  0.05 and †P  0.001 vs. control.
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Fig. 4. Changes in admittance gain (A and B), phase (C), and coherence (D) in the frequency domain before (control; black), during L-NAME inhibition of NOS
(L-NAME; red) alone, and in combination with tempol quenching of O2 (L-NAME  tempol; blue). B: magnification of changes in admittance gain against a
linear scale of frequency between 0.06 and 0.3 Hz, highlighting different slopes of stages 1 and 2 and the transition point (circles). Values are means  SE
(dotted lines; n  6 mice).
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magnified in Fig. 4B and plotted on a linear frequency axis
to facilitate comparisons of the slopes. In view of the two
stages characterizing the myogenic mechanism in the time
domain, each admittance gain trace was analyzed using mul-
tiple linear regression to evaluate differences in slopes and
transition points. The transition points for each period were
constrained to occur after 0.15 Hz. The resulting best-fit
regression lines are shown as dotted lines in Fig. 4B, and the
slopes and transition points are summarized in Table 4. Two
stages were identified in the myogenic frequency range. It is
striking that the transition point between stages (identified by
circles) was not statistically different among the three experi-
mental periods and that the slopes of myogenic responses in the
low-frequency range (labeled as stage 2) were the same during
the three conditions. The admittance gain for the higher fre-
quency range between 0.15 and 0.25 Hz, labeled stage 1,
showed a significantly increased slope above control in the
L-NAME group, an effect normalized by tempol treatment. We
postulate that these two stages in the myogenic response in the
frequency domain correspond to the two stages identified in the
time domain. In each case, the slope of stage 1 only was
augmented by inhibition of NO and inhibited by suppression of
O2. In the time domain, this was the initial stage after the
increase in RPP, while in the frequency domain the responsive
region was restricted to the higher frequencies of the myogenic
range (stage 1 in Fig. 4B). By this reasoning, stage 2 in Fig. 4B
was comparable to stage 2 of the myogenic response in the
time domain, both of which were insensitive to L-NAME and
tempol.
Tempol treatment after L-NAME during spectral analysis
experiments reduced RPP to the control level seen before
L-NAME. This is a potential confounding factor in the inter-
pretation of these data, as the RPP drop alone could alter the
admittance gain (71, 90). To test this, the admittance gain was
determined in other animals before and during NOS inhibition
with L-NAME, followed by a period in which fluctuations in
RPP were reduced to the mean level recorded during tempol
treatment. The admittance gain, phase angle, and coherence of
the RPP/RBF relationship for these experiments are presented
in Fig. 5. The forced reduction in mean RPP from 118 to 79
mmHg during NOS inhibition with L-NAME caused a small
nonsignificant reduction in the magnitude of the admittance
gain from 1.6  0.2 to 1.3  0.2 relative units, with a small
reduction of the corner frequency at which this occurred by
0.022 Hz. The lower RPP also caused a consistent offset in the
myogenic gain response, amounting to 0.034  0.004 Hz
between 0.2 and 0.1 Hz. Nevertheless, the overall gain and
phase relationships between RPP and RBF after L-NAME were
similar at high and normal RPP levels (Table 5).
DISCUSSION
Our study provides a comprehensive description of the
dynamic characteristics of blood flow autoregulation in the
mouse kidney using a novel combination of time- and frequen-
Table 4. Slopes for the two stages and the transition point between the stages of the renal myogenic response based on a
linear frequency scale (Fig. 4B)
RPP, mmHg RBF, ml·min1·g KW1
Slope, 
gain/Hz
Transition, HzStage 1 Stage 2
Control 83 2 5.6  0.6 1.8  0.9 4.2 0.5 0.16  0.02
L-NAME 116  6 2.5 0.3 17.7  2.4* 4.6 0.6 0.18  0.01
L-NAME  tempol 85 2 2.4  0.2 0.8  3.1 4.9 0.5 0.21  0.03
Values are means  SE; n  6 mice. *P  0.001 vs. control.
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Fig. 5. Changes in admittance gain during control (black), and L-NAME
inhibition of NOS when mean RPP was 118 mmHg (red) and then reduced
to 79 mmHg by aortic constriction (blue). Values are means  SE (n  6
mice).
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cy-domain analyses. We provide new evidence that autoregu-
latory adjustments in RVR following a step increase in RPP are
essentially complete within 15 s and are mediated exclusively
by the myogenic mechanism(s). This intrinsic, rapid myogenic
response involves two phases or stages that do not require
MD-TGF to achieve a complete autoregulatory response. Stage
1 produces a 50–60% increase in RVR by 3 s, and stage 2
accounts for the remaining 40–50% by 13 s. A slight overshoot
was complete by 18 s. In addition, on the basis of responses to
L-NAME and tempol, our data implicate interactive roles for
superoxide and NO in the modulation of dynamic elements in
myogenic RBF autoregulation in the healthy kidney. As might
be expected, inhibition of NO synthesis accentuates the auto-
regulatory response, presumably by reducing NO-mediated
vasodilation. However, subsequent dismutation of the vasocon-
strictor O2 restores the original speed and strength of the
myogenic constrictor response, despite continued NOS inhibi-
tion. In this regard, our data support the hypothesis that the
predominant action of NO is to suppress a O2-mediated
vasoconstrictor effect, perhaps secondary to quenching O2,
rather than exerting a direct vasodilatory action. A new finding
is that these interactions are primarily targeted to the initial,
most rapid phase of the myogenic mechanism and have little
influence on the second slower phase of myogenic vasocon-
striction, or on overall, steady-state RBF autoregulation.
An abrupt increase in RPP has been used previously to
investigate dynamic aspects of RBF autoregulation in dogs,
rats, and mice. A study on anesthetized dogs showed that RBF
returned to the control level 25 s after a 40-mmHg step increase
in RPP (31). Similar to our mouse results, Young and Marsh
(96) showed that RBF autoregulation in the rat was complete
15 s after a 10- to 20-mmHg RPP step. In their study, an
immediate passive response in RVR lasted 1 s, followed by
an initial active stage that produced a 50% increase in RVR at
3 s and a subsequent slower increase in RVR that completed
the autoregulatory response by 15 s (96). Measurements of
tubular fluid flow changes in the early distal tubule after the
RPP step led them to conclude that the rather sluggish MD-
TGF response could not operate within the time frame of these
autoregulatory RVR responses. Daniels and Arendshorst (17)
reached a similar conclusion based on the time delay required
for activation and completion of the MD-TGF mechanism.
Using stop-flow micropuncture methodology, these investiga-
tors found a 15-s delay in the single nephron MD-TGF re-
sponse following a step change in late proximal tubule perfu-
sion. The MD-TGF response attained 50% of its eventual
maximum 27 s after the increase in perfusion rate, which is too
slow to participate in the autoregulatory response. This is in
accordance with an earlier study showing no measurable effect
of MD-TGF inhibition by UO on the static RBF autoregulatory
curve (18). In the exposed juxtamedullary preparation of rats,
autoregulatory adjustments of afferent arteriolar diameter re-
sponded quickly to a step increase in RPP (86). The decrease
in diameter took place between 6 and 24 s when MD-TGF was
active and between 6 and 13 s during abrogation of MD-TGF
by papillectomy. Thus MD-TGF complimented the myogenic
response only after 13 s. In the hydronephrotic rat kidney,
which lacks tubules and thus any MD-TGF, afferent arteriolar
diameter responses to a step increase in RPP were complete
within 15 s (56).
Drummond and colleagues (24, 25, 27) performed in vivo
RBF studies in anesthetized mice assessing the dynamic
changes in RVR to a step increase in RPP. Two rates of change
in RVR were noted with complete autoregulation attained in
15–20 s. As we observed, the first active stage took place in the
1- to 5-s time window, and the second stage was completed by
15–20 s after the RPP increase. This was the case whether
MD-TGF was normal or inhibited by acute volume expansion
(25), indicating a predominant contribution from the myogenic
mechanism. Genetic deletion of acid-sensing ion channel 2
proteins or knockdown of epithelial Na channel -subunit,
which are postulated mechanosensors in the renal vasculature,
slowed the initial stage by 50% without affecting the second
stage (24, 27). It is noteworthy that, in our study, NO and O2
inhibition also primarily affected the initial rapid stage (stage
1) of the myogenic response. Thus stage 1 of the myogenic
mechanism appears to be selectively responsive to physiolog-
ical signals compared with the slower second stage that is
relatively insensitive. This is similar to earlier observations in
other vascular beds that identified two stages in the myogenic
response. In that case, an initial, rate-sensitive mechanism
preceded a second static response that was not influenced by
the rate of pressure change (4, 5, 21).
Our data are consistent with earlier reports showing effective
renal autoregulatory response to an abrupt increase in RPP that
is complete in 15–25 s after the RPP step in multiple species.
Moreover, the data indicate that this is due to a rapid myogenic
mechanism without significant contribution from the slower
MD-TGF mechanism. In contrast, rodent studies by Just and
colleagues (19, 20, 34–36) have shown that the autoregulatory
response of RVR was not completed until 50–60 s after a
20-mmHg RPP increase. They identified three active compo-
nents in the RVR response: an initial active stage lasted 4–5 s,
a second stage ending 20–25 s later, and a third stage taking
place between 25 and 60 s. During inhibition of MD-TGF with
furosemide, the third stage was abolished in wild-type mice
and normal rats, whereas the first two stages persisted in
roughly the same time intervals as during control conditions
(34–36). Thus, according to our interpretation, their data are
consistent with the most rapid two phases being associated
with the myogenic mechanism, while the third mechanism is
due to MD-TGF. However, their assumption that the myogenic
Table 5. Lack of effect of changing RPP on frequency analysis of admittance gain and resonance frequency during nitric
oxide synthase inhibition by L-NAME
RPP, mmHg RBF, ml·min1·g KW1
Admittance Gain at Resonance
Peak, relative units Resonance Frequency, Hz
Control 80 2 7.3 0.7 1.1 0.04 0.283  0.002
L-NAME high 118 5 3.2 0.7 1.6 0.2 0.278  0.006
L-NAME low 79 2 2.6 0.4 1.3 0.2 0.256  0.007*
Values are means  SE; n  6 mice. *P  0.001 vs. control.
F840 MODULATION OF RENAL AUTOREGULATION BY NO AND SUPEROXIDE
AJP-Renal Physiol • doi:10.1152/ajprenal.00461.2015 • www.ajprenal.org
Downloaded from www.physiology.org/journal/ajprenal at Univ of North Carolina Chapel Hill (152.002.071.053) on August 12, 2019.
mechanism takes place between 1 and 4–7 s and that the
MD-TGF begins at 4–7 s and ends at 25–30 s (20, 36, 37) is
at variance with our conclusion. The persistence of an auto-
regulatory response in the 5- to 20-s time window during
furosemide inhibition of MD-TGF was interpreted as an unde-
fined mechanism, independent of the myogenic and MD-TGF
mechanisms, whereas our data clearly establish that RBF
autoregulation in this time window is achieved by the second
stage of the myogenic response. Ge et al. (25) also find a
similar second stage of the RVR response when MD-TGF is
inhibited by extracellular fluid volume expansion. It is likely
that a marked difference in the time interval required for the
completion of RBF autoregulation is the basis of the divergent
conclusions, but the underlying reason for the difference is not
known.
As previously described (34), our time-domain analysis
shows a modulatory action of MD-TGF on the rate of the
myogenic mechanism such that the latter was increased when
MD-TGF was inhibited. This is likely a function of the exper-
imental design in which reduced RPP before the step increase
in RPP reduces flow to the MD and elicits a vasodilatory signal
from the MD-TGF mechanism (34). This persists during the
first seconds following the step increase in RPP and tends to
oppose the initial stage of the rapid increase in RVR mediated
by the myogenic mechanism. This was not apparent in the
frequency domain, where admittance gain associated with the
myogenic mechanism was not altered after MD-TGF inhibition
with mannitol/UO. In contrast to the step change in RPP,
continuous random fluctuations in RPP do not produce a clear
temporal sequence that results in unambiguous interaction
between myogenic and MD-TGF components. Thus, when
studied in the frequency domain, MD-TGF might not influence
admittance gain in the myogenic frequency range of 0.06–0.2
Hz, as has been previously noted by others (2, 18).
Our control values for frequency analysis are consistent with
previous studies of renal autoregulation using frequency do-
main analysis on anesthetized rats. These studies consistently
show admittance gain responses with shoulders at 0.2 Hz and
0.02 Hz, which are the transition points attributed to the onset
of the myogenic and MD-TGF mechanisms, respectively (13,
15, 18, 33). A previous study by Iliescu et al. (30) in conscious
mice found that relative admittance gain fluctuated between 1.8
and 2.5 relative units (5–8 dB) at frequencies 	0.2 Hz,
whereas our relative admittance gain fluctuated between 1.2
and 1.3 units in the same frequency range. Between 0.2 and 0.1
Hz, the relative admittance gain in conscious mice fell to 0.7
units (3 dB); our relative admittance gain decreased from 1.2
to 0.7 units over the same frequency range. Thus our data for
admittance gain are in close agreement with this earlier study.
Also, our data are almost identical to a decrease in relative
admittance gain from 1.2 to 0.7 between 0.2 and 0.1 Hz
reported for rats anesthetized with pentobarbital (18). In rats
anesthetized with isoflurane, Cupples et al. (16) showed rela-
tive gain increasing from 1.1 to 1.8 between 0.35 and 0.2 Hz,
at which point gain decreased to 0.45 between 0.2 and 0.1 Hz.
In a another study using the same protocol, these investigators
reported an increase in relative gain from 1.3 to 1.8 between
1.0 and 0.2 Hz and then a decrease to 0.75 (5 dB) at 0.07 Hz
(80). Thus our current data on admittance gain in the control
period are in close agreement with previous studies, with the
caveat that differences might be expected with respect to
species used, state of anesthesia, the kidney preparation, and
type of AP fluctuations employed.
The efficiency of steady-state RBF autoregulation, based on
the plateau phase, is not affected by NOS inhibition (6, 8, 20,
35, 58, 67), whereas the dynamic components of the myogenic
mechanism are clearly influenced by the presence and absence
of NO. Changes in the time domain include an accelerated and
pronounced increase in RVR with obvious oscillations (Fig. 2)
(19, 20, 35, 95). In the frequency-domain, L-NAME caused an
exaggerated resonance peak at 0.25 Hz and a stronger myo-
genic response identified by an accelerated reduction in admit-
tance gain in the myogenic frequency range (Fig. 4) (79, 80,
87, 90, 91). Thus NO inhibition did not affect overall steady-
state RBF autoregulation, but did markedly augment the rate at
which it is achieved. The potentiation of an intrarenal mecha-
nism(s) appears to be independent of hypertension per se, as
the myogenic response is not altered markedly by ANG II,
AVP, or phenylephrine-induced hypertension of a magnitude
similar to that of NOS inhibition (Fig. 3) (20, 35, 71, 80).
Multilinear analysis of the RVR response to the RPP step
revealed that the target of NOS inhibition was the initial stage
of the myogenic response, which became accelerated and
stronger and was converted to oscillations. Such oscillations
became superimposed onto the second stage with diminishing
amplitude, while the fundamental mean slope of the second
stage remains unchanged. This was also evident in the fre-
quency domain when NOS inhibition strongly increased the
slope of admittance gain at the higher end of the myogenic
range and amplified the resonance peak at 0.25 Hz. At lower
frequencies in the myogenic range, between 0.06 and 0.1 Hz,
the slope of admittance gain was unaffected by NOS inhibition.
A similar two-stage response of admittance gain after L-NAME
was seen in rats by Wang and coworkers (88, 89, 91), where
distinct regions in admittance gain were noted between 0.25-
0.1 Hz and 0.1-0.06 Hz. However, this was not readily appar-
ent during control conditions (88, 89, 91). As noted above, two
distinct components or stages in the RVR response in the time
domain were also reported by Drummond and colleagues (24,
25, 27) between 3 and 25 s after a RPP step.
In addition to eliciting vasodilation, NO blunts vasoconstric-
tion produced by G protein-coupled agonists, such as ANG II,
endothelin-1, and the catecholamines norepinephrine or phen-
ylephrine (9, 38, 40). Exaggerated vasoconstriction by one of
these agonists might explain the enhanced myogenic response
during NOS inhibition. However, ANG II and catecholamines
do not potentiate the myogenic response in the time domain
(20, 35) or the frequency domain (1, 71, 80) as markedly as
that seen during NOS inhibition of NO production. On the
other hand, O2 does enhance the myogenic response by an
action independent of NO (50). Thus we conclude that NOS
inhibition leads to an exaggerated myogenic response that is
likely mediated by reduced vasodilatory activity from NO
and/or enhanced O2-mediated vasoconstriction.
The incorporation of superoxide removal with tempol after
NOS inhibition is an important component of our studies, as it
probes the direct cause of the increased vascular reactivity
associated with L-NAME treatment. The actions of L-NAME
may be readily explained by elimination of the vasodilatory
actions of NO, but our observations suggest a more complex
explanation. The action of L-NAME on the myogenic autoreg-
ulatory response was reversed by tempol in both the time and
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frequency domains. The opposite actions of NO synthesis
inhibition with L-NAME and O2 dismutation by tempol sug-
gest counteracting influences of NO and O2 on the myogenic
mechanism. Such a paracrine-like interaction was apparent
during the initial, but not the secondary, stage of the myogenic
response in our time-series experiments. In addition, a similar
interaction was suggested only at higher frequencies in the
myogenic range in spectral analyses of RBF autoregulation,
which we have identified in Fig. 4B as stage 1. Collectively,
these findings are consistent with the proposal that the inhibi-
tory action of NO on the myogenic response results from
quenching of O2 in stage 1 of the myogenic response and does
not involve a direct vasodilatory action involving activation of
soluble guanylyl cyclase (sGC) and cGMP production. If this
were not the case, one would expect the vasoconstrictor action
of L-NAME to persist after O2 dismutation with tempol, which
was not observed. This is also supported by data showing that
tempol alone has a relatively minor effect on the autoregulatory
response to a step increase in RPP compared with the pro-
nounced effect after NO inhibition (N. G. Moss and W. J.
Arendshorst, unpublished observations). This proposed role for
NO is at variance with a recent publication showing that an
effect of L-NAME on the myogenic response similar to that
reported here was reversed by cGMP formation induced by
continual pharmacological stimulation of sGC (19). Overall
steady-state RBF autoregulation efficiency was attenuated by
up to 33%, although most investigators report that NO donors,
L-arginine, or acetylcholine do not affect the efficiency of
overall steady-state autoregulation (28, 45, 67, 68). Adding to
controversy in this area are the puzzling results on mice
deficient in the various NOS isoforms from which Dautzenberg
et al. (20) concluded that eNOS activity attenuates the myo-
genic response in a manner independent of NO production.
Physiological NO stimulation by endothelin-induced activation
of endothelin B receptors attenuates the myogenic response
without affecting overall autoregulation (79). Early studies
showed modulation of RPP-induced steady-state constriction
of the preglomerular vasculature by cGMP-dependent vasodi-
lators, such as sodium nitroprusside and ANP (11). Other
studies suggest cGMP-independent actions, since ANP or ad-
ministration of L-arginine failed to completely reverse the
actions of NOS inhibition on RBF autoregulation and admit-
tance gain in the myogenic frequency range (91). The mecha-
nisms by which NO produces vasodilation of afferent arterioles
is concentration dependent, with low concentrations (900
nM) acting through cGMP, whereas higher concentration ex-
erts an effect independent of cGMP (83). There is evidence
suggesting that the NO/sGC pathway can cause renal vasodi-
lation via a phosphodiesterase 3 and cAMP-dependent pathway
(78). Thus physiological activation of autoregulatory responses
by abrupt changes or fluctuations in RPP and shear stress may
recruit different pathways from those engaged by constant
pharmacological activation of NO.
Several studies on isolated vessels have supported a prom-
inent role for O2 in potentiating vasoconstriction in resistance
arterioles. Increased luminal pressure rapidly increased NA-
DPH oxidase production of ROS in isolated mouse tail arteri-
oles (66), hamster gracilis muscle arteries (44), carotid arteries
(84), cerebral arteries (26), and mouse afferent arterioles (50,
53). This was associated with enhanced myogenic vasocon-
striction, perhaps by promoting Ca2 entry or sensitivity of the
VSMC contractile apparatus (26, 66). O2 facilitates opening of
L-type Ca2 channels during VMSC membrane depolarization
(85). Studies on isolated mouse afferent arterioles have shown
that O2 plays an important role in potentiating contractile
responses to vasoconstrictors, such as ANG II and thrombox-
ane A2 (49, 53) and in the steady-state myogenic response to
increased intraluminal pressure (49, 50, 53). O2 is thought to
enhance in vitro renal myogenic contraction largely indepen-
dent of NO (50), although its actions in modulating MD-TGF
appear to be either by limiting bioavailability of NO (54, 93) or
a direct action on the afferent arteriole (54). The mutual
quenching action between NO and O2 limits bioavailability of
both radicals and is thought to modulate afferent arteriolar
reactivity to ANG II (12). Thus, when both are generated in
physiologically relevant amounts, an excess of NO will pro-
duce the same response as a deficiency in O2. This might
explain steady-state studies reporting no effect of tempol on
RPP-induced constriction of the afferent arteriole of the iso-
lated, perfused hydronephrotic kidney (69) or on steady-state
autoregulation of RBF and medullary blood flow under basal
conditions (23).
We recognize that the use of tempol to inactivate the
vasoconstrictor O2 by dismutation could result in the genera-
tion of the vasodilator H2O2, which may play a role in the
vasodilatory response. However, we believe that the renal
hemodynamic actions of tempol are primarily due to dismuta-
tion of O2 and the removal of its vasoconstrictor influence
rather than increased H2O2 levels. This conclusion is based on
the published work of other investigators showing that the
potentiating action of O2 on myogenic vasoconstriction in
arteries and arterioles during increased intraluminal pressure is
inhibited by tempol, but not by catalase (26, 50). Also, the
enhanced myogenic response of afferent arterioles of SHR is
normalized by the O2 scavenger tempol or by the Nox2
inhibitor gp91ds, findings that led to the conclusion that Nox2-
derived O2 may contribute to the enhanced myogenic response
(76). In mice, isolated afferent arterioles increased O2 produc-
tion in response to increased luminal pressure, which magni-
fied myogenic constriction and was inhibited by tempol but
unaffected by catalase, even though exogenous H2O2 is re-
ported to blunt the myogenic constriction of renal arterioles
(50). Similar observations have been made on the cerebral
circulation. Increased luminal pressure in rat middle cerebral
arteries increased O2 and H2O2 generation that resulted in
augmentation of myogenic constriction (26). The potentiation
was inhibited by tempol in the presence or absence of poly-
ethylene glycol catalase (26), indicating a primary action of O2
rather than H2O2. Moreover, H2O2 commonly acts as vasodi-
lator in circulatory beds, such as cerebral, coronary, mesen-
teric, and skeletal muscle, and may function as an endothelium-
dependent hyperpolarization factor and an activator of potas-
sium channels (10, 14, 47, 55, 64, 70); both dilator and
hyperpolarizing actions are expected to blunt rather than po-
tentiate pressure-induced myogenic constriction.
Animal studies have demonstrated that O2 dismutation by
tempol attenuates renal vasoconstriction induced by ANG II,
AVP, endothelin, and norepinephrine, and that this vasocon-
strictor action of O2 may involve quenching of NO and also an
action independent of NO (39, 40, 65). On the other hand, our
laboratory (65) has shown previously that O2 enhances the
renal vasoconstrictor action of AVP primarily by limiting the
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bioavailability of NO, suggesting different roles as a function
of stimulus. The action of L-NAME on the myogenic autoreg-
ulatory response in our studies of renal autoregulation was
reversed by tempol in both the time and frequency domain,
suggesting a direct vasoconstrictor action of O2 in the absence
of NO. In isolated mouse afferent arterioles, O2 enhances the
myogenic constriction by an action independent of NO (50). In
addition, a recent modeling study of the actions of NO and O2
on the myogenic mechanism in afferent arterioles concludes
that activation of sGC by NO is of less importance than the
intracellular quenching of O2 by NO (51). We believe our
observations are consistent with the conclusion that NOS
inhibition leads to an exaggerated myogenic response as a
result of attenuated NO production, less quenching of O2, and
the augmented actions of the vasoconstrictor O2.
Perspectives
Our studies clearly demonstrate that complete autoregulation
of RBF following an abrupt RPP step is accomplished in two
stages by the autonomous myogenic response of VSMC in the
renal microcirculation of mice. While this does not exclude
MD-TGF from a role in the autoregulatory response during
more gradual pressure changes, abrupt alterations in RPP are
effectively countered by the myogenic mechanism within 15 s.
Following NOS inhibition, the enhanced speed and strength in
stage 1 appear to be dependent on increased O2 bioavailabil-
ity, as both are reversed by quenching of O2 with tempol.
These observations provide a new perspective on the control of
the myogenic mechanism in RBF autoregulation that has im-
portant implications for renal function in conditions of oxida-
tive stress as well as health.
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